Hong Kong-listed innovative drug stocks gained ground, with Tongyuan Kang Pharmaceutical rising more than 7%, while Lepu Bio, Shijiazhuang Pharmaceutical Group, and CanSino Biologics each rose more than 3%, and Kelun Botai Biologics and Hansoh Pharmaceutical each rose more than 2%.
Hong Kong-listed innovative drug stocks gained ground, with Tongyuan Kang Pharmaceutical rising more than 7%, while Lepu Bio, Shijiazhuang Pharmaceutical Group, and CanSino Biologics each rose more than 3%, and Kelun Biotech and Hansoh Pharmaceutical each rose more than 2%.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
What is MATE? An Analysis of the Asset, Project Positioning, and Current Status
-
2
CORE and Satoshi Token Market Performance: 2023 Review and November 2026 Status
-
3
How is ZNX (ZENEX)? What are the future development prospects for ZNX?
-
4
Chinese Mainland Crypto Trading Platforms and Software Recommendations? Regulatory Status and Risk Analysis
-
5
OKX Futures Trading Tutorial and Beginner's Guide
-
6
Bloomberg survey shows China's factory activity expanded, but growth slowed for the first time since July.
-
7
KERMIT Coin: Trading Status and Channel Analysis
-
8
LG CNS completes construction of 30MW hyperscale AI data center in Jakarta, Indonesia
-
9
SK Square plans to return at least 4.3 trillion Korean won to shareholders.
-
10
SHIB Price Trends and Latest Developments Analysis
Markets Today
Recommended Reading







